Integer Holdings Corporation (ITGR) स्टॉक विश्लेषण

कंपनी का अवलोकन

Integer Holdings Corporation operates as a specialized contract development and manufacturing entity within the healthcare sector, specifically focusing on medical devices across the United States, Costa Rica, Puerto Rico, Ireland, and international markets. The company provides critical products designed for interventional cardiology, structural heart applications, heart failure management, peripheral vascular care, and neurological solutions, positioning it firmly in the medical device industry. This enterprise employs approximately 11,000 individuals and holds a market capitalization of $3.04 billion, generating total annual revenue of $1.85 billion. These financial figures indicate that the company functions as a significant mid-to-large-cap player within the specialized medical device manufacturing landscape, possessing substantial operational scale to support its global contract development footprint.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $1.85 billion alongside a net income of $102.83 million and an EBITDA of $377.19 million, revealing a cost structure where non-operating expenses, interest, and taxes consume a significant portion of gross earnings. Free cash flow stands at $76.88 million, which represents the actual cash remaining after capital expenditures, providing the company with a baseline level of financial flexibility despite its large debt obligations. Profitability analysis shows a gross margin of 27.4%, an operating margin of 12.8%, and a profit margin of 5.5%, indicating that while the manufacturing process retains a decent portion of revenue, overhead costs and other operational expenses heavily impact the bottom line. The balance sheet displays a cash balance of $17.16 million against total debt of $1.32 billion, resulting in a debt-to-equity ratio of 75.44, which characterizes a highly leveraged financial position rather than a conservative one. Liquidity is supported by a current ratio of 3.32, suggesting the company holds sufficient current assets to cover its short-term liabilities multiple times over. Return on equity is recorded at 6.1% while return on assets sits at 4.7%, metrics that suggest management effectiveness is currently constrained by the high leverage on the balance sheet and the capital-intensive nature of the medical device manufacturing business.

मूल्यांकन आकलन

Valuation metrics show a trailing P/E ratio of 29.99 compared to a forward P/E of 12.00, implying that the market is pricing in a substantial expected expansion in future earnings relative to current profitability levels. The price-to-book ratio stands at 1.70, indicating that the market values the company at a 70% premium over its tangible book value, reflecting confidence in its intangible assets and future service contracts. Alternative valuation measures include a price-to-sales ratio of 1.64 and an EV/EBITDA of 11.35, suggesting the stock is valued moderately relative to its revenue generation and earnings power before interest, taxes, depreciation, and amortization. Historical price data indicates a 52-week high of $127.56 and a 52-week low of $62.00, placing the current trading price within a wide range that reflects significant market volatility over the past year. The stock exhibits a beta of 0.71, which means its price volatility is approximately 29% lower than the broader market, suggesting a defensive characteristic often found in specialized healthcare infrastructure companies.

Growth & Income

Revenue growth for the trailing twelve months was 5.0%, while earnings growth surged to 52.9%, indicating that earnings are expanding significantly faster than top-line revenue, likely driven by margin expansion or cost efficiencies. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all of its net income back into operations, debt reduction, or business expansion rather than distributing cash to shareholders. This retention of earnings supports the capital-intensive requirements of contract manufacturing and product development within the medical device sector. The overall growth and income profile is defined by robust earnings acceleration and a zero-dividend policy, prioritizing capital allocation for internal growth over immediate shareholder income distributions.